In a country where cardiac care costs continue to burden millions, Ahmedabad-based Medkart has introduced a game-changing innovation: India’s first room-temperature stable generic Nicorandil tablets, making heart medication more accessible, affordable, and logistically convenient.
This innovation eliminates the need for cold-chain storage, reducing logistical challenges and making the medication more accessible and affordable for patients across diverse regions.
Nicorandil is widely prescribed for the treatment of chronic stable angina. Due to its sensitivity to temperature and humidity, its storage has traditionally required stringent cold-chain logistics. This requirement often poses significant challenges, especially in rural and semi-urban areas where maintaining cold-chain infrastructure is difficult.
Medkart's room-temperature stable Nicorandil tablets are manufactured under WHO-GMP-certified facilities, ensuring high-quality standards. By eliminating the need for refrigeration, the company significantly reduces distribution costs, allowing the medication to be priced up to 80% lower than its branded counterparts.
Dr Ramesh Mehta, a senior cardiologist based in Ahmedabad, said, "Ensuring that a cardiac drug like Nicorandil remains effective without refrigeration is a major step forward, particularly for patients in remote regions. We’ve long seen efficacy compromised due to storage issues. This advancement will save lives and improve treatment consistency."
